Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Misinformation Contributing To Slower Biosimilar Uptake, Execs Claim

‘All Stakeholders Responsible’ For Change

Executive Summary

Dispelling myths around biosimilar efficacy and safety may be crucial to driving uptake of biosimilars, executives from Sandoz and Boehringer Ingelheim have argued in an opinion piece in the journal, BioDrugs, as they asserted it was the “responsibility of all stakeholders to challenge biosimilar disparagement and misinformation when encountered.”

You may also be interested in...



Sandoz’ Saynor Insists US Biosimilars Market Is Stepping Up

Sandoz CEO Richard Saynor says he sees promising signs from the US biosimilars market that suggest it is beginning to meet its potential, albeit remaining many years behind the European market.

Sandoz Talks US Biosimilars And Misinformation

Increasing access and use of lower cost biosimilars by combatting disparagement and misinformation is more important now than ever, as the COVID-19 pandemic cripples economies across the globe, argues Sandoz’ executive director for scientific affairs, Hillel Cohen.

FDA And FTC Join Forces On Biosimilars

Two agencies to take action against false or misleading communications about biosimilars, impediments to sampling, and anticompetitive patent settlement agreements; to hold public workshop in March.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel